Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 685.00 GBp
Change Today +4.50 / 0.66%
Volume 228.7K
CLIN On Other Exchanges
Symbol
Exchange
London
OTC US
Stuttgart
As of 11:35 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

clinigen group plc (CLIN) Snapshot

Open
683.50 GBp
Previous Close
680.50 GBp
Day High
693.00 GBp
Day Low
679.50 GBp
52 Week High
07/22/15 - 694.50 GBp
52 Week Low
08/8/14 - 359.25 GBp
Market Cap
751.5M
Average Volume 10 Days
326.3K
EPS TTM
0.20 GBp
Shares Outstanding
109.7M
EX-Date
03/12/15
P/E TM
34.9x
Dividend
3.56 GBp
Dividend Yield
0.52%
Current Stock Chart for CLINIGEN GROUP PLC (CLIN)

Related News

No related news articles were found.

clinigen group plc (CLIN) Related Businessweek News

No Related Businessweek News Found

clinigen group plc (CLIN) Details

Clinigen Group plc provides specialty pharmaceutical products and services in the United Kingdom and internationally. The company’s Clinical Trials Supply business provides commercial medicines for use in clinical and comparator trial drug sourcing. Its Specialty Pharmaceuticals business offers Cardioxane to prevent the chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic adult breast cancer; Foscavir for the treatment of cytomegalovirus retinitis in HIV patients and Acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised patients, as well as cytomegalovirus-viremia and CMV disease in patients; Savene for the treatment of anthracycline extravasation; and VIBATIV, a bactericidal injectable lipoglycopeptide antibacterial antibiotic against Gram-positive bacteria, including resistant pathogens, such as methicillin-resistant Staphylococcus aureus. The company’s Global Access Programs business is involved in the consultancy, development, management, and implementation of access programs to manage access to unlicensed, licensed, or end-of-lifecycle products. It serves patients, pharmaceutical/biotechnology companies, and contract research organizations. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

107 Employees
Last Reported Date: 10/9/14
Founded in 2008

clinigen group plc (CLIN) Top Compensated Officers

Group Chief Executive Officer and Executive D...
Total Annual Compensation: 590.0K GBP
Group Chief Financial Officer, Company Secret...
Total Annual Compensation: 346.0K GBP
Group Deputy Chief Executive Officer, Chief O...
Total Annual Compensation: 426.0K GBP
Compensation as of Fiscal Year 2014.

clinigen group plc (CLIN) Key Developments

Clinigen Group Plc Announces Management Changes

Clinigen Group Plc announced that in light of the Idis acquisition, the company has taken the opportunity to review and restructure its management team to ensure effective management across the enlarged business. Consequently, Shaun Chilton has been promoted from COO to Deputy CEO of the Group. Martin Abell will join at the beginning of August 2015 as a director, and CFO elect during a period of handover from Robin Sibson.

Clinigen Group plc Provides Earnings Guidance for the Year Ended June 30, 2015

Clinigen Group plc provided earnings guidance for the year ended June 30, 2015. For the year, the company’s revenues increased in excess of 45% to not less than £183.6 million (2014: £126.6 million). Gross profit increased in excess of 30%, mainly driven by greater than 25% growth in Specialty Pharmaceuticals (SP) gross profits and the acquisition of Idis. Underlying EBITDA up at least 20% to not less than £32.2 million (2014: £26.8 million). Strong cash generation and, as at 30 June 2015, closing net debt was £78.0 million.

Clinigen Group Mulls Acquisitions

Clinigen Group Plc (AIM:CLIN) is seeking acquisitions. Clinigen Group plc said, “Clinigen continues with its strategy of organic growth supplemented with acquisitions.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLIN:LN 685.00 GBp +4.50

CLIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLIN.
View Industry Companies
 

Industry Analysis

CLIN

Industry Average

Valuation CLIN Industry Range
Price/Earnings 35.1x
Price/Sales 4.1x
Price/Book 7.7x
Price/Cash Flow 45.1x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLINIGEN GROUP PLC, please visit www.clinigengroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.